Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according to ...

Biocartis’ Idylla EGFR Mutation Test has secured the EU Technical Documentation Assessment and Quality Management System certificate, making it the first Idylla Test to achieve Class C companion ...

Using artificial intelligence, Garvan Institute researchers have found potential cancer drivers hidden in so-called ‘junk’ regions of DNA, opening up possibilities for a new approach to diagnosis and ...

NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...

Genetic disorders can occur due to mutations in one gene (monogenic), multiple genes (multifactorial inheritance), and mutation in one or more chromosomes. Point mutations are where one nucleotide in ...

HSP90 buffers certain BRCA1 mutations, allowing them to persist in humans and promote resistance to PARP inhibitor treatments Low-dose HSP90 inhibition restored PARP inhibitor sensitivity in ...

Epidermal growth factor receptor (EGFR) is a protein on the surface of your cells that helps them grow. When the gene that codes for EGFR has a mutation, it affects the way this protein works, causing ...

Researchers from Black Diamond Therapeutics Inc. presented the discovery and preclinical characterization of a novel brain-penetrant BRAF class I/II/III mutation inhibitor, BDTX-4933.